ClinicalTrials.gg
CompletedNCT02530905Updated May 17, 2021Results posted

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

A Phase 1 interventional study of SRP-4045 and Placebo in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 3 sites in United States. Open to male participants aged 7 Years to 21 Years. Per ClinicalTrials.gov, last updated 2021-05-17.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
7 Years to 21 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
20th of 25
12 · median 24
Started
2015
with 2 others
Phase 1
5 of 27
1 open now
Registered
9th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2015, is one of 5 in phase 1, and was the 9th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 21 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

This is a first-in-human dose-titration and open-label extension study to assess safety, tolerability, and pharmacokinetics of SRP-4045 in advanced-stage Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 45 skipping.

Read the detailed description

This is a randomized, placebo-controlled dose-titration study to assess safety, tolerability, and pharmacokinetics of 4 dose levels of SRP-4045 in genotypically confirmed advanced-stage DMD patients with deletions amenable to exon 45 skipping.

After completion of the dose-titration portion of the study and SRP-4045 is determined to be safe, all patients will be evaluated on open-label SRP-4045 for the duration of the study.

Safety, including adverse event monitoring, routine laboratory assessments, and cardiac testing will be monitored through the duration of the dose-titration and open-label portions of the study.

Clinical efficacy will be assessed at regularly scheduled study visits via quality of life questionnaires and tests of pulmonary and upper extremity function through the duration of the dose-titration and open-label portions of the trial.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne muscular dystrophy
  • Exon Skipping
04

Who can participate

Ages eligible
7 Years to 21 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genotypically confirmed DMD (amenable to exon 45 skipping).
  • Stable cardiac and pulmonary function.
  • Limited or no ambulation.
  • On a stable dose of oral for at least 24 weeks OR has not received corticosteroids for at least 24 weeks.

Exclusion criteria

Exclusion Criteria:

  • Current or previous treatment with the experimental agents SMT C1100 (BMN-195) or PRO045.
  • Other experimental treatment in the past 12 weeks.
  • If on cardiac medication, must be on a stable dose for the past 12 weeks.
  • Major surgery within the past 3 months.

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Placebo comparator
    Placebo (double-blind dose titration)

    Participants with genotypically confirmed Duchenne muscular dystrophy (DMD) characterized by deletions amenable to exon 45 skipping will receive placebo-matching to casimersen intravenous (IV) infusions, once weekly over approximately 12 weeks in the double-blind period.

    Drug: Placebo

  • Experimental
    SRP-4045 (double-blind dose titration)

    Participants with genotypically confirmed DMD characterized by deletions amenable to exon 45 skipping will receive weekly IV infusions of casimersen at four escalating dose levels, each for at least 2 weeks: 4 milligrams per kilograms (mg/kg) during Week 1 to Week 2, followed by 10 mg/kg during Week 3 to Week 4, followed by 20 mg/kg during Week 5 to Week 6, followed by 30 mg/kg beginning at Week 7 and continue over approximately Week 12 in the double-blind period.

    Drug: SRP-4045

  • Experimental
    SRP-4045 (open label extension period)

    All participants who completed double blind period will be enrolled to receive casimersen 30 mg/kg once weekly, for up to Week 144 in the open label extension period.

    Drug: SRP-4045

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse event (AE) was any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with the investigational drug. AEs also included abnormal physical examination findings (Physical examination were conducted per protocol and any clinically significant abnormal findings were recorded in medical history if pre-existing or addressed as an AE if new or worsening). TEAEs was defined as AEs that started, worsened, or became serious on or after the start of first infusion through 148 weeks. Number of participants with TEAEs were reported.

    Time frame: Baseline up to Week 148

  2. Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs

    Laboratory parameters included serum chemistry (hepatic chemistry and renal chemistry), hematology, coagulation, and urinalysis. Number of participants with potentially clinically significant abnormal finding were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potentially clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

    Time frame: Baseline up to Week 148

  3. Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs

    Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potential clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

    Time frame: Baseline up to Week 148

  4. Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs

    Twelve-lead ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECG reported as TEAEs were presented here. The Investigator determined whether abnormal assessment results were potentially clinically significant or not.

    Time frame: Baseline up to Week 148

  5. Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)

    Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study.The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECHO were reported.

    Time frame: Baseline up to Week 148

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Casimersen

    Maximum Concentration (Cmax) of casimersen in plasma was evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  2. Time to Reach Maximum Plasma Concentration (Tmax) of Casimersen

    Time to reach maximum plasma concentration (Tmax) of casimersen was evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  3. Area Under Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Casimersen in Plasma

    Area under the concentration-time curve from time zero to the last quantifiable concentration of casimersen in plasma were evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  4. Area Under Concentration-Time Curve From Time Zero Pre-dose to Twenty-Four Hours Post-dose (AUC0-24) of Casimersen in Plasma

    Area under concentration-time curve from time zero pre-dose to twenty-four hours post-dos of casimersen in plasma were evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  5. Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Casimersen in Plasma

    Area under the concentration-time curve from time zero extrapolated to the infinity of casimersen in plasma was evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  6. Apparent Volume of Distribution at Steady State (Vss) of Casimersen

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution at steady state of casimersen was evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  7. Elimination Half-life (T1/2) of Casimersen

    T1/2 is the time measured for the plasma concentration of drug to decrease by one half. T1/2 of casimersen was evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  8. Total Clearance (CL) of Casimersen

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL of casimersen was evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  9. Mean Residence Time Extrapolated to Infinity (MRTinf) of Casimersen

    MRTinf = AUMCinf/AUCinf - T/2, where T was the infusion duration, and AUMCinf was the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method. MRTinf of casimersen was evaluated.

    Time frame: Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP

  10. Double-Blind Period: Renal Clearance (CLR) of Casimersen

    Renal clearance was calculated using the partial AUC0-24 from the non-compartmental analysis in plasma and AE0-24. AUC0-24 was defined as area under the plasma concentration-time curve, from time 0 to 24 hours after completion of dosing. AE0-24 was defined as total cumulative amount excreted from 0 to 24 hours. Summarized data of all urine collection intervals are reported.

    Time frame: 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 and 12 (for 30 mg/kg arm) in double-blind period

07

Results

Posted May 17, 2021

Participant flow

The study was conducted at 3 sites in United States.

Double-Blind Period (12 Weeks)
Participant flow — Double-Blind Period (12 Weeks)
MilestoneDouble-Blind Period: PlaceboDouble-Blind Period: CasimersenOpen Label Extension Period: Casimersen
Started480
Received 4 mg/kg080
Received 10 mg/kg080
Received 20 mg/kg080
Received 30 mg/kg080
Completed480
Not completed000
Open Label Extension Period (132 Weeks)
Participant flow — Open Label Extension Period (132 Weeks)
MilestoneDouble-Blind Period: PlaceboDouble-Blind Period: CasimersenOpen Label Extension Period: Casimersen
Started0012
Completed0011
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse event (AE) was any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with the investigational drug. AEs also included abnormal physical examination findings (Physical examination were conducted per protocol and any clinically significant abnormal findings were recorded in medical history if pre-existing or addressed as an AE if new or worsening). TEAEs was defined as AEs that started, worsened, or became serious on or after the start of first infusion through 148 weeks. Number of participants with TEAEs were reported.

Time frame:
Baseline up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsDouble-Blind Period: PlaceboDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Number of Participants With Treatment Emergent Adverse Events (TEAEs)4533712
PrimaryNumber of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs

Laboratory parameters included serum chemistry (hepatic chemistry and renal chemistry), hematology, coagulation, and urinalysis. Number of participants with potentially clinically significant abnormal finding were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potentially clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

Time frame:
Baseline up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs
ParticipantsDouble-Blind Period: PlaceboDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Serum chemistry: Hepatic chemistry000000
Serum chemistry: Renal chemistry000000
Hematolgy: Leukocytes000024
Hematolgy: Neutrophils000046
Coagulation: Platelet count000022
Urinalysis000001
PrimaryNumber of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs

Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were potentially clinically significant or not. Potential clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

Time frame:
Baseline up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs
ParticipantsDouble-Blind Period: PlaceboDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs000011
PrimaryNumber of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs

Twelve-lead ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECG reported as TEAEs were presented here. The Investigator determined whether abnormal assessment results were potentially clinically significant or not.

Time frame:
Baseline up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs
ParticipantsDouble-Blind Period: PlaceboDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEs000001
PrimaryNumber of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)

Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study.The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with potentially clinically significant abnormalities in ECHO were reported.

Time frame:
Baseline up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)
ParticipantsDouble-Blind Period: PlaceboDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)000000
SecondaryMaximum Plasma Concentration (Cmax) of Casimersen

Maximum Concentration (Cmax) of casimersen in plasma was evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Casimersen
Nanogram per milliliter (ng/mL)Double-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Maximum Plasma Concentration (Cmax) of Casimersen13700 ± 25.039400 ± 11.764400 ± 27.4119000 ± 33.6115000 ± 31.5
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Casimersen

Time to reach maximum plasma concentration (Tmax) of casimersen was evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Median · Hour
Time to Reach Maximum Plasma Concentration (Tmax) of Casimersen
HourDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Time to Reach Maximum Plasma Concentration (Tmax) of Casimersen1.11 (0.92 to 1.22)1.03 (0.93 to 1.17)1.03 (0.83 to 1.22)0.94 (0.83 to 1.18)0.95 (0.78 to 1.08)
SecondaryArea Under Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Casimersen in Plasma

Area under the concentration-time curve from time zero to the last quantifiable concentration of casimersen in plasma were evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Geometric mean · Hour*nanogram per milliliter (hr*ng/mL)
Area Under Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Casimersen in Plasma
Hour*nanogram per milliliter (hr*ng/mL)Double-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Area Under Concentration-time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Casimersen in Plasma23100 ± 29.559500 ± 16.2101000 ± 17.7188000 ± 27.4182000 ± 33.8
SecondaryArea Under Concentration-Time Curve From Time Zero Pre-dose to Twenty-Four Hours Post-dose (AUC0-24) of Casimersen in Plasma

Area under concentration-time curve from time zero pre-dose to twenty-four hours post-dos of casimersen in plasma were evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Geometric mean · h*ng/mL
Area Under Concentration-Time Curve From Time Zero Pre-dose to Twenty-Four Hours Post-dose (AUC0-24) of Casimersen in Plasma
h*ng/mLDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Area Under Concentration-Time Curve From Time Zero Pre-dose to Twenty-Four Hours Post-dose (AUC0-24) of Casimersen in Plasma23200 ± 29.459500 ± 16.1101000 ± 17.7188000 ± 27.4182000 ± 33.8
SecondaryArea Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Casimersen in Plasma

Area under the concentration-time curve from time zero extrapolated to the infinity of casimersen in plasma was evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Casimersen in Plasma
h*ng/mLDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Area Under the Concentration-Time Curve From Time Zero Extrapolated to the Infinity (AUCinf) of Casimersen in Plasma23300 ± 29.558300 ± 16.0101000 ± 17.7189000 ± 27.5182000 ± 33.9
SecondaryApparent Volume of Distribution at Steady State (Vss) of Casimersen

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution at steady state of casimersen was evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Geometric mean · Liter per kilogram (L/kg)
Apparent Volume of Distribution at Steady State (Vss) of Casimersen
Liter per kilogram (L/kg)Double-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Apparent Volume of Distribution at Steady State (Vss) of Casimersen0.369 ± 24.40.343 ± 12.50.407 ± 23.40.319 ± 31.40.367 ± 28.9
SecondaryElimination Half-life (T1/2) of Casimersen

T1/2 is the time measured for the plasma concentration of drug to decrease by one half. T1/2 of casimersen was evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Mean · Hour
Elimination Half-life (T1/2) of Casimersen
HourDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Elimination Half-life (T1/2) of Casimersen2.92 ± 0.9853.29 ± 0.6403.71 ± 0.6163.82 ± 0.7413.45 ± 0.359
SecondaryTotal Clearance (CL) of Casimersen

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL of casimersen was evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Geometric mean · Liters per hour per kilogram (L/h/kg)
Total Clearance (CL) of Casimersen
Liters per hour per kilogram (L/h/kg)Double-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Total Clearance (CL) of Casimersen0.177 ± 29.10.181 ± 15.90.205 ± 18.50.163 ± 27.70.180 ± 35.0
SecondaryMean Residence Time Extrapolated to Infinity (MRTinf) of Casimersen

MRTinf = AUMCinf/AUCinf - T/2, where T was the infusion duration, and AUMCinf was the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method. MRTinf of casimersen was evaluated.

Time frame:
Pre-infusion, 5 to 10 minutes, 1, 1.5, 2, 4, 6, 8, 12, 16, and 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 (for 30 mg/kg arm) in DBP and Week 60 (for 30 mg/kg arm) in OLEP
Reported as:
Geometric mean · Hour
Mean Residence Time Extrapolated to Infinity (MRTinf) of Casimersen
HourDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Mean Residence Time Extrapolated to Infinity (MRTinf) of Casimersen2.08 ± 13.51.89 ± 16.11.98 ± 12.71.96 ± 16.62.04 ± 10.3
SecondaryDouble-Blind Period: Renal Clearance (CLR) of Casimersen

Renal clearance was calculated using the partial AUC0-24 from the non-compartmental analysis in plasma and AE0-24. AUC0-24 was defined as area under the plasma concentration-time curve, from time 0 to 24 hours after completion of dosing. AE0-24 was defined as total cumulative amount excreted from 0 to 24 hours. Summarized data of all urine collection intervals are reported.

Time frame:
0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours post-dose at Weeks 1 (for 4 mg/kg ), 3 (for 10 mg/kg arm), 5 (for 20 mg/kg arm), 7 and 12 (for 30 mg/kg arm) in double-blind period
Reported as:
Geometric mean · L/h/kg
Double-Blind Period: Renal Clearance (CLR) of Casimersen
L/h/kgDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kg
Double-Blind Period: Renal Clearance (CLR) of Casimersen0.137 ± 25.80.162 ± 22.60.209 ± 29.00.177 ± 34.2

Adverse events

Collected over From start of study drug administration up to Week 148. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Period: Placebo0/4 (0%)0/4 (0%)4/4 (100%)
Double-Blind Period: Casimersen 4 mg/kg0/8 (0%)0/8 (0%)5/8 (62.5%)
Double-Blind Period: Casimersen 10 mg/kg0/8 (0%)0/8 (0%)3/8 (37.5%)
Double-Blind Period: Casimersen 20 mg/kg0/8 (0%)0/8 (0%)3/8 (37.5%)
Double-Blind Period: Casimersen 30 mg/kg0/8 (0%)1/8 (12.5%)7/8 (87.5%)
Open Label Extension Period: Casimersen 30 mg/kg0/12 (0%)3/12 (25%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventDouble-Blind Period: PlaceboDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
Septic embolusInfections and infestations0/40/80/80/81/81/12
vena cava thrombosisVascular disorders0/40/80/80/81/81/12
bacteraemiaInfections and infestations0/40/80/80/81/81/12
Femur fractureInjury, poisoning and procedural complications0/40/80/80/80/81/12
Tibia fractureInjury, poisoning and procedural complications0/40/80/80/80/81/12
Most frequent other events
Showing 10 of 89
Most frequent other events
EventDouble-Blind Period: PlaceboDouble-Blind Period: Casimersen 4 mg/kgDouble-Blind Period: Casimersen 10 mg/kgDouble-Blind Period: Casimersen 20 mg/kgDouble-Blind Period: Casimersen 30 mg/kgOpen Label Extension Period: Casimersen 30 mg/kg
NasopharyngitisInfections and infestations1/41/80/80/81/89/12
Dermatitis contactSkin and subcutaneous tissue disorders2/40/80/80/80/82/12
Procedural painInjury, poisoning and procedural complications1/40/80/82/83/84/12
VomitingGastrointestinal disorders0/40/80/82/82/84/12
HeadacheNervous system disorders0/41/80/80/82/84/12
Upper respiratory tract infectionInfections and infestations0/40/80/80/80/84/12
CoughRespiratory, thoracic and mediastinal disorders0/40/80/80/80/84/12
NauseaGastrointestinal disorders0/41/81/81/80/83/12
Tinea versicolourInfections and infestations1/40/80/80/80/81/12
Ligament sprainInjury, poisoning and procedural complications1/40/80/80/80/80/12

Baseline characteristics

Safety set included all randomized participants who received at least 1 dose of study drug (casimersen or placebo) in double-blind period.

Age, Continuous
Age, Continuous(Years)Double-Blind Period: PlaceboDouble-Blind Period: CasimersenTotal
Mean12.0 ± 2.1614.4 ± 3.2913.6 ± 3.09
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Period: PlaceboDouble-Blind Period: CasimersenTotal
Female000
Male4812
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind Period: PlaceboDouble-Blind Period: CasimersenTotal
Hispanic or Latino011
Not Hispanic or Latino4711
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-Blind Period: PlaceboDouble-Blind Period: CasimersenTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American000
White4610
More than one race000
Unknown or Not Reported000
08

Study locations

3 sites
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Oct 2018, 35 months.

Results were first posted in May 2021, 2 years 7 months after primary completion.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2015
First posted
Aug 21, 2015
StartActual
Oct 8, 2015
Primary completionActual
Oct 3, 2018
CompletionActual
Oct 3, 2018
Results first posted
May 17, 2021
Last update
May 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02530905
Responsible party
Sponsor
First posted
Aug 21, 2015
Start date
Oct 8, 2015
Primary completion
Oct 3, 2018
Completion
Oct 3, 2018
Results posted
May 17, 2021
Last update
May 17, 2021

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Casimersen

Start the discussion